Like pharmaceutical companies globally - which used to enjoy a preferential exchange rate in Venezuela - Indian producers have been left badly stung by the collapse of the bolivar currency
The rules make India's health warnings on tobacco products the world's most stringent, along with Thailand
Uber is suing Ola for $7.5 million to compensate for lost revenue and goodwill, alleging the Indian market leader created about 94,000 fake user accounts with the ride-hailing service and used them to make more than 405,000 false bookings
The USTR has placed India on its "priority watch" list for two years in a row, saying the country's patent laws unfairly favour local drug makers.
Several companies, including Indian units of Abbott Laboratories and Pfizer Inc, and domestic firms like Cipla Ltd and Macleods Pharmaceuticals, went to the Delhi High Court to try to get the ban lifted.
It is one of 42 drug-making factories in India that the FDA has banned in recent years
The next hearing on Pfizer's plea is slated for March 21
A notice issued by the Indian Health Ministry at the weekend said that a government-appointed committee of experts had found that the banned combinations were "likely to involve risk to human beings, whereas safer alternatives to the said drug are available."
The alleged fraud includes the use of fake bills.
Most of the extra spending in the Budget is in fact an accounting entry that shifts the cost of an interest subsidy to the agriculture Budget that was previously borne by the finance ministry
Dinesh Thakur is famous for exposing Ranbaxy safety problems
Some questions cited concerns that larger warnings can hurt tobacco farmers and boost illicit trade.
The government wants to introduce a nationwide goods and services tax to revive its stalled reform programme.
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
US firm Mylan NV received a stern warning from the FDA in August for faulty manufacturing practices at three of its India drugmaking plants.
Uber and Ola both welcomed the move as a step in the right direction.
A directive this year to ban all vehicles older than 15 years has been delayed and previous city governments have often ignored court orders to address pollution woes.
India rejects patent on Pfizer's arthritis drug
Cipla has agreed to buy two generics businesses in the United States in an all-cash deal worth $550 million.
MAT has damaged investor confidence